Future oncology最新文献_第2页

Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma. 一项新诊断多发性骨髓瘤患者静脉输注isatuximab 30分钟的研究总结。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-27 DOI: 10.1080/14796694.2026.2652723

Enrique M Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquín Martínez-López, Lionel Karlin, Corina Oprea, Yi Li, Ercem Kodas, Jesus San-Miguel

引用次数: 0

Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy. 前列腺癌局部治疗后生化复发患者的现实世界治疗模式。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-29 DOI: 10.1080/14796694.2026.2651959

Rana R McKay, Nasreen Khan, Neal D Shore, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Daniel E Spratt

{"title":"Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy.","authors":"Rana R McKay, Nasreen Khan, Neal D Shore, Guifang Chen, Vlasta Hlebec, Shankar Srinivasan, Daniel E Spratt","doi":"10.1080/14796694.2026.2651959","DOIUrl":"10.1080/14796694.2026.2651959","url":null,"abstract":"Aim: Describe real-world anticancer treatment patterns in the USA among patients with prostate cancer (PC) who experience biochemical recurrence (BCR) following radical prostatectomy (RP) or radiation therapy (RT), stratified by prostate-specific antigen doubling time (PSA-DT).Methods: Retrospective, observational cohort study using the Optum® PC electronic medical record database (2012-2023). Patients with BCR were stratified into high-/low-risk groups based on PSA-DT of <12/≥12 months. A sensitivity analysis defined risk status using a ≤9-/>9-month cutoff.Results: The study included 2,981 patients with BCR in the RP cohort and 697 in the RT cohort. Median follow-up was 30.8 months (Q1-Q3: 18.1-50.8). Any treatment use was higher among high-risk BCR patients (RP: 67.1% vs 54.9%; RT: 52.8% vs 28.7%). After RP, most patients received salvage RT (high-risk: 41.3%; low-risk: 40.7%), followed by androgen-deprivation therapy (ADT) monotherapy (high-risk: 30.2%; low-risk: 22.8%) and ADT plus androgen receptor pathway inhibitor (ARPI) (high-risk: 11.9%; low-risk: 3.7%). After RT, ADT monotherapy (high-risk: 22.9%; low-risk: 12.3%) and ADT plus ARPI (high-risk: 16.5%; low-risk 4.9%) were most common. Sensitivity analyses showed similar results.Conclusions: These findings demonstrate that ADT remains the predominant standard of care, whereas ADT plus ARPI is infrequently used, even among high-risk BCR patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1301-1309"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer. 评价宗厄替尼治疗her2突变型非小细胞肺癌的疗效。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-22 DOI: 10.1080/14796694.2026.2658641

Jinyong Kim, Myung-Ju Ahn

引用次数: 0

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery. 对LAURA研究结果的简单回顾：对不能通过手术切除的egfr突变的非小细胞肺癌患者进行放化疗后使用奥西替尼。

IF 2.6 4区医学

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-04-27 DOI: 10.1080/14796694.2026.2652543

Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Virote Sriuranpong, Eduardo Cronemberger, Toshiaki Takahashi, Yotsawaj Runglodvatana, Ming Chen, Xiangning Huang, Ellie Grainger, Dana Ghiorghiu, Toon van der Gronde, Suresh S Ramalingam

引用次数: 0

Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis. 抗CLDN18.2治疗晚期或转移性胃癌、胃-食管交界区和食管癌CLDN18.2阳性的疗效和安全性：一项系统回顾和meta分析

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-16 DOI: 10.1080/14796694.2026.2659354

Yaping Zhang, Shangbin Kao, Dian Li, Canlong Yan, Biao Huang, Hongming Fang

{"title":"Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis.","authors":"Yaping Zhang, Shangbin Kao, Dian Li, Canlong Yan, Biao Huang, Hongming Fang","doi":"10.1080/14796694.2026.2659354","DOIUrl":"https://doi.org/10.1080/14796694.2026.2659354","url":null,"abstract":"Purpose: The optimal treatment strategy for advanced or metastatic gastric, gastro-esophageal junction or esophageal carcinomas expressing Claudin-18 isoform 2 (CLDN18.2) remains inadequately defined and requires further investigation.Methods: A systematic search was conducted to identify randomized controlled trials and single-arm studies.Results: Four randomized controlled trials comprising five cohorts compared anti-CLDN18.2-based therapies with chemotherapy or physician's choice. Anti-CLDN18.2 therapy, primarily consisting of first-line zolbetuximab combined with chemotherapy, significantly improved progression-free survival (PFS) (hazard ratios [HR] 0.564; 95% confidence interval [CI]: 0.417-0.711) and overall survival (OS) (HR 0.716; 95% CI: 0.631-0.802), along with enhanced 1- and 2-year survival rates. However, higher rates of nausea, neutropenia, and vomiting were observed in patients treated with zolbetuximab-based regimens. A single-arm meta-analysis, which included ten cohorts from seven trials, demonstrated that antibody-drug conjugates (ADCs) exhibited greater antitumor activity compared to zolbetuximab-based regimens.Conclusion: Anti-CLDN18.2 therapies, particularly first-line zolbetuximab plus chemotherapy, significantly improve PFS and OS in advanced gastric, gastro-esophageal junction, or esophageal carcinoma compared to standard treatments. ADCs have shown promising antitumor activity in single-arm studies, suggesting the need for confirmatory randomized trials. Standardized definitions for CLDN18.2 positivity and high expression are urgently needed.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251123719.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":2.6,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study. Alirocumab联合西米单抗治疗晚期免疫难治性转移性非小细胞肺癌：一项正在进行的多中心II期研究

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-01 Epub Date: 2026-04-06 DOI: 10.1080/14796694.2026.2648863

Eziafa I Oduah, Tian Zhang, Sin-Ho Jung, Thomas E Stinchcombe, Neal Ready, Jeffrey Crawford, Jeffrey M Clarke, Jhanelle E Gray, Scott J Antonia

{"title":"Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.","authors":"Eziafa I Oduah, Tian Zhang, Sin-Ho Jung, Thomas E Stinchcombe, Neal Ready, Jeffrey Crawford, Jeffrey M Clarke, Jhanelle E Gray, Scott J Antonia","doi":"10.1080/14796694.2026.2648863","DOIUrl":"10.1080/14796694.2026.2648863","url":null,"abstract":"Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rationale for therapeutic PCSK9 inhibition as a strategy to overcome resistance to immune checkpoint blockade. Building on this evidence, we present the scientific rationale and study design of TOP2201, an ongoing single-arm phase II trial evaluating the addition of the PCSK9 inhibitor alirocumab to anti-PD-1 therapy in patients with metastatic NSCLC who have experienced disease progression on prior immune checkpoint inhibitor-based regimens. The primary endpoint is objective response rate, with secondary endpoints assessing additional efficacy outcomes and safety. Findings from TOP2201 are expected to generate preliminary clinical and safety data on this combination strategy in the immunorefractory NSCLC setting.Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT05553834.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1065-1072"},"PeriodicalIF":2.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147621873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. SUNRAY-01试验方案：olomorasib和pembrolizumab联合化疗或不联合化疗治疗KRAS G12C NSCLC的创新研究设计

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-01 Epub Date: 2026-04-06 DOI: 10.1080/14796694.2026.2651961

Solange Peters, Maximilian Hochmair, Kathryn C Arbour, Luis Paz-Ares Rodriguez, Martin Reck, Ticiana Leal, Colin R Lindsay, Lu Shun, William Nassib William, Alexander I Spira, Joshua K Sabari, Bjørn Henning Grønberg, Makoto Nishio, Timothy F Burns, Nicolas Girard, Frederico Capuzzo, Alyson Merced, Nicolas Fasnacht, Carla Visseren-Grul, Marcelo V Negrao

引用次数: 0

Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan. 非小细胞肺癌患者的实际治疗模式和医疗负担：日本的回顾性数据库研究

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-01 Epub Date: 2026-03-18 DOI: 10.1080/14796694.2026.2645989

Linghua Xu, Sona-Sanae Aoyagi, Yusuke Nukui, Tomoyo Oguri, Kanae Togo

{"title":"Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan.","authors":"Linghua Xu, Sona-Sanae Aoyagi, Yusuke Nukui, Tomoyo Oguri, Kanae Togo","doi":"10.1080/14796694.2026.2645989","DOIUrl":"10.1080/14796694.2026.2645989","url":null,"abstract":"Aim: We investigated treatment patterns and healthcare resource utilization (HRU) to clarify unmet medical needs in second and later lines among Japanese patients with advanced non-small cell lung cancer (NSCLC).Methods: This retrospective study included patients with NSCLC having first-line treatment from a claims database (January 2019-December 2024). Treatment patterns, time to treatment discontinuation (TTD), and HRU were described for patients with/without actionable genomic alteration (AGA) therapy.Results: Overall, 22,886 patients (with AGA, 7,831; without AGA, 15,055) were included. In patients with AGA, targeted therapy (48.6%), platinum doublet (12.1%), and chemo monotherapy (10.4%) were common second-line treatments, with median TTD 7.5, 4.3, and 3.0 months, respectively. In patients without AGA, chemo monotherapy (45.1%), ICI monotherapy (17.8%), and platinum doublet (13.9%) were the most prescribed second-line treatments with relatively short median TTD (2.7, 3.7, and 3.2 months, respectively). Hospitalization rates were higher in patients with second-line treatment duration <3 versus ≥3 months (incidence/100 person-years, 67-88 vs 35-38).Conclusion: Treatment patterns were heterogeneous with short durations that were associated with higher rates of HRU. The study findings highlight the challenge of current treatments, and need for effective treatment options in clinical practice in Japan.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1083-1094"},"PeriodicalIF":2.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence. GLP-1受体激动剂和免疫检查点抑制剂治疗：机制和临床证据的叙述性回顾。

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-01 Epub Date: 2026-04-03 DOI: 10.1080/14796694.2026.2654735

Connor Frey

{"title":"GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence.","authors":"Connor Frey","doi":"10.1080/14796694.2026.2654735","DOIUrl":"10.1080/14796694.2026.2654735","url":null,"abstract":"Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressive mechanisms, including regulatory T-cells, myeloid-derived suppressor cells, and pro-inflammatory macrophages, can limit durable anti-tumor responses. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond metabolic comorbidity management, functioning as metabolic-immunologic adjuvants capable of reprogramming the tumor microenvironment in obese patients receiving ICIs. A literature search was conducted in PubMed/MEDLINE through December 2025 using MeSH headings related to glucagon-like peptide-1 receptor agonists and immune checkpoint inhibitors. Mechanistically, GLP-1R signaling activates cAMP-PKA-AMPK pathways that suppress NF-κB-driven inflammation and promote macrophage repolarization, improving CD8 T-cell metabolic fitness, enhancing central memory formation, and reducing lipid-induced T-cell exhaustion. Real-world observational data across renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and neuroendocrine neoplasms suggest improved overall survival, fewer immune-related adverse events, and lower cardiometabolic complications with concurrent GLP-1RA and ICI therapy. Pharmacovigilance concerns regarding pancreatitis, ICI-induced diabetes, and immune-related toxicities remain incompletely characterized. This review critically appraises mechanistic insights, real-world evidence, and safety considerations, proposing a translational-clinical research agenda to prospectively validate GLP-1RAs as rational adjuncts to checkpoint blockade.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1221-1231"},"PeriodicalIF":2.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma. MISTOSUS: Viscum album提取物辅助治疗复发性可切除骨肉瘤的II期试验。

IF 2.6 4区医学

Future oncology Pub Date : 2026-04-01 Epub Date: 2026-03-06 DOI: 10.1080/14796694.2026.2638986

Katharine Offer, Marcus Reif, Clark Andersen, Jian Wang, Nancy Gordon, Karen Moody

{"title":"MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma.","authors":"Katharine Offer, Marcus Reif, Clark Andersen, Jian Wang, Nancy Gordon, Karen Moody","doi":"10.1080/14796694.2026.2638986","DOIUrl":"10.1080/14796694.2026.2638986","url":null,"abstract":"Relapsed resectable osteosarcoma carries a dismal prognosis of 30% 12-month post-relapse event-free survival (PREFS-12). Surgery remains the primary therapy for metastatic pulmonary osteosarcoma with the role for adjuvant therapy still undefined. There is an urgent need for effective nontoxic adjuvant therapies to improve PREFS following complete resection of metastases. Viscum album extract (Iscador® P, Iscador AG, Arlesheim, Switzerland) is a fermented aqueous extract manufactured from the leaves, stems, and berries of the white-berried hemiparasitic plant from the European mistletoe (Viscum album L.) grown on pine trees (P = Pini). It is a promising therapeutic antineoplastic agent with preclinical and clinical evidence of benefit in osteosarcoma. This includes a pilot study showing 55% PREFS in 9 pediatric, adolescent and young adult (AYA) patients with a median follow-up of 84 months. Viscum album extract has a long history of use in Europe and a track record of safety in children which allowed for the opening of a Phase II trial in the US to test the efficacy of Viscum album extract to improve PREFS in children and AYAs with relapsed osteosarcoma. Secondary outcomes include effects on quality of life and changes in immune profiling of tumor and serum samples.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"901-909"},"PeriodicalIF":2.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13048566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0